All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FLAMSA-like regimens: When should we use these for transplantation conditioning in AML?

During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to Mohamad Mohty, Hôpital Saint-Antoine and Sorbonne University, Paris, FR. We asked, When should we use FLAMSA regimens for transplantation conditioning in AML?

FLAMSA-like regimens: When should we use these for transplantation conditioning in AML?

In this video, Mohty summarizes data on allogeneic transplantation presented at the EBMT virtual meeting, regarding the use of FLAMSA (fludarabine, cytarabine, and amsacrine) conditioning regimens for patients with primary refractory or relapsed AML. Mohty believes FLAMSA options are proving to be useful and effective, giving hope to patients waiting for treatment.

 

Share: